Top 120+ Biotech Companies In Boston In 2021
← Visit blog

Top 120+ Biotech Companies In Boston In 2021

Updated on March 10th, 2021

Top 120+ Biotech Companies In Boston In 2021

A hand curated list of 120+ top biotech companies in Boston.
Whether you run a digital agency, a B2B company, or just want to connect with fast growing companies, this is the list for you.
In our premium lists, we also include: • 20+ data points for each company
• Services they’re likely to outsource
• CEO Information & Email
If you’re interested in our premium lists, consider subscribing to our monthly report of tech companies.


Table Of Contents

  1. Pieris Pharmaceuticals ($10M to $50M)
  2. AZTherapies (Less than $1M)
  3. Alloplex Biotherapeutics (Less than $1M)
  4. 3Derm Systems ($1M to $10M)
  5. Gelesis ($10M to $50M)
  6. Fluent BioSciences (Less than $1M)
  7. KeraFAST ($1M to $10M)
  8. Jnana ($1M to $10M)
  9. Psy Therapeutics ($1M to $10M)
  10. Nanoview Biosciences ($1M to $10M)
  11. Imbria Pharmaceuticals ($1M to $10M)
  12. GliaCure (Less than $1M)
  13. Precision Biopsy (Less than $1M)
  14. Manifold Bio ($10M to $50M)
  15. Yumanity Therapeutics ($1M to $10M)
  16. Wave Life Sciences ($1M to $10M)
  17. DermBiont (Less than $1M)
  18. Nido Biosciences ($10M to $50M)
  19. resTORbio ($1M to $10M)
  20. ConcertAI ($10M to $50M)
  21. Nara Logics (Less than $1M)
  22. Tal Medical (Less than $1M)
  23. SOPHiA GENETICS ($50M to $100M)
  24. ConquerX ($10M to $50M)
  25. Ginkgo Bioworks ($10M to $50M)
  26. Xontogeny (Less than $1M)
  27. Samsara Therapeutics ($1M to $10M)
  28. Cytrellis Biosystems (Less than $1M)
  29. Asimov ($1M to $10M)
  30. Cardurion Pharmaceuticals ($10M to $50M)
  31. IGC BIO ($10M to $50M)
  32. Compass Therapeutics ($10M to $50M)
  33. Binx Health ($10M to $50M)
  34. Yobe Inc. (Less than $1M)
  35. Aldatu Biosciences (Less than $1M)
  36. CoWin Biosciences ($10M to $50M)
  37. Biomiic ($1M to $10M)
  38. Invetx ($10M to $50M)
  39. Motif FoodWorks (Less than $1M)
  40. UV Light Care ($1M to $10M)
  41. Synspira ($1M to $10M)
  42. LikeMinds ($1M to $10M)
  43. Zepteon ($10M to $50M)
  44. Flaskworks ($1M to $10M)
  45. QMENTA ($1M to $10M)
  46. Akili Interactive Labs ($10M to $50M)
  47. BrainSpec (Less than $1M)
  48. Ensoma (Less than $1M)
  49. Kumuda ($10M to $50M)
  50. Candescent Eye Holdings ($10M to $50M)
  51. Sonde Health (Less than $1M)
  52. Embark ($1M to $10M)
  53. Advanced Proteome Therapeutics (Less than $1M)
  54. Eliem Therapeutics ($1M to $10M)
  55. NeuroBo Pharmaceuticals ($1M to $10M)
  56. FluoroPharma (Less than $1M)
  57. Emulate ($1M to $10M)
  58. Boston MicroFluidics ($10M to $50M)
  59. Adeo Health Science (Less than $1M)
  60. Cambrian Innovation ($10M to $50M)
  61. Valo Health ($10M to $50M)
  62. Sample6 ($1M to $10M)
  63. Bioarray Therapeutics (Less than $1M)
  64. NuProbe ($1M to $10M)
  65. Symbiotix Biotherapies (Less than $1M)
  66. Pear Therapeutics ($10M to $50M)
  67. Life Biosciences ($1M to $10M)
  68. Karuna Therapeutics ($1M to $10M)
  69. TetraScience (Less than $1M)
  70. Syntimmune ($10M to $50M)
  71. Atalanta Therapeutics ($10M to $50M)
  72. Klogene Therapeutics, Inc. ($1M to $10M)
  73. Beta Bionics ($1M to $10M)
  74. CleanBreak ($1M to $10M)
  75. Center for Regenerative Medicine ($1B to $10B)
  76. ORIG3N ($1M to $10M)
  77. Mytide Therapeutics (Less than $1M)
  78. Akouos ($1M to $10M)
  79. Prilenia (Less than $1M)
  80. Inozyme ($10M to $50M)
  81. Joyn Bio ($1M to $10M)
  82. Biofourmis (Less than $1M)
  83. Rhythm Pharmaceuticals ($1M to $10M)
  84. Aerovate Therapeutics ($10M to $50M)
  85. Back Bay Life Science Advisors (Less than $1M)
  86. Centrexion ($1M to $10M)
  87. Accreon ($10M to $50M)
  88. Medrhythms (Less than $1M)
  89. Symbiosis Pharmaceutical Services ($1M to $10M)
  90. Partner Therapeutics ($1M to $10M)
  91. Pyxis Oncology ($10M to $50M)
  92. BrickBio (Less than $1M)
  93. Orbita ($1M to $10M)
  94. Portela Soni Medical (Less than $1M)
  95. Anodyne Nanotech (Less than $1M)
  96. Entrada Therapeutics ($1M to $10M)
  97. Motus Therapeutics ($100M to $500M)
  98. Exonics Therapeutics ($1M to $10M)
  99. CATALOG ($1M to $10M)
  100. Profility ($1M to $10M)
  101. Reverie Labs (Less than $1M)
  102. Entrega Bio (Less than $1M)
  103. Scorpion Therapeutics ($10M to $50M)
  104. Meenta ($1M to $10M)
  105. Cure Forward ($1M to $10M)
  106. Elucid Bio ($1M to $10M)
  107. Oncolinx (Less than $1M)
  108. SciFluor Life Sciences ($1M to $10M)
  109. SeromYx Systems ($10M to $50M)
  110. Proterris ($10M to $50M)
  111. Leuko (Less than $1M)
  112. ImmuneID ($10M to $50M)
  113. Atea Pharmaceuticals ($1M to $10M)
  114. CONTINUUS Pharmaceuticals (Less than $1M)
  115. Miach Orthopaedics ($1M to $10M)
  116. Farcast ($1M to $10M)
  117. Cerevel Therapeutics ($1M to $10M)
  118. GRO Biosciences (Less than $1M)
  119. inviCRO ($10M to $50M)
  120. Alivio Therapeutics ($1M to $10M)


  1. Pieris Pharmaceuticals ($10M to $50M)

    Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need. Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $32M raised in November, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  2. man and woman sitting at table


  3. AZTherapies (Less than $1M)

    AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. Advancing a growing pipeline to treat patients with few therapeutic options, the Company’s lead candidate, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of the disease. The Phase 3 COGNITE trial in early Alzheimer’s disease is fully enrolled and expected to complete in late 2020. Following the lead program, AZTherapies is advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), and other indications. AZTherapies is a private company founded in 2011 and headquartered in Boston, Massachusetts.

    • Less than $1M annual revenues
    • 11-50 employees
    • $14.8M raised in September, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  4. people standiunmg


  5. Alloplex Biotherapeutics (Less than $1M)

    Alloplex Biotherapeutics is a privately held Boston based cellular therapeutics company. Their lead oncology therapeutic is a PBMC-derived multicellular adoptive immunotherapy which they call SUPLEXA cells. They use proprietary leukocyte activator cell lines (ENLiST cells), which are engineered from a common tumor cell line to express an array of immunomodulatory ligands designed to specifically engage and activate various subsets of peripheral blood mononuclear cells (PBMC) through their native receptors. Alloplex has developed SUPLEXA cells through the use of an all-human in vitro assay which not only models the intended ex vivo activation of patient PBMC but is, in fact, the actual procedure to be deployed in the clinic. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in July, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  6. people sitting beside rectangular brown table with laptops


  7. 3Derm Systems ($1M to $10M)

    3Derm is a cost-effective, skin imaging system that allows non-dermatologists to take clinical-quality 3D skin images remotely. Two million Americans develop skin cancer every year. With 3Derm, dermatologists can review images taken at medical kiosks and other referral sites to efficiently monitor high volumes of patients’ lesions while reserving in-office appointment times for those patients whose images indicate a more alarming condition. 3Derm cuts down on wait times reduces healthcare spending and save lives. Two million Americans develop skin cancer every year. Patients currently monitor their skin through routine dermatology appointments, which are scheduled as frequently as six times per year for high-risk cases. These are both expensive and inconvenient. 3Derm Systems is developing a low-cost skin monitoring solution that allows patients to take clinical-quality 3D images from the comfort of their own homes. Dermatologists can use the uploaded images to efficiently monitor high volumes of patients' lesions while reserving in-clinic appointment times for patients whose images indicate a more alarming condition. 3Derm aims to revolutionize the field of teledermatology by providing greater access to dermatological care. Some patients use handheld digital cameras or apps to take and send images via teledermatology. 3Derm allows patients to keep their local dermatologist instead of using a telemedicine service and uses clinical quality features that ensure every image maximizes diagnostic usefulness for both the patient and the physician.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $1.7M raised in July, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  8. two men using computers


  9. Gelesis ($10M to $50M)

    Gelesis is a clinical stage biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients. Gelesis100, our lead product, is an orally- administered smart pill which is constructed of materials that are General Recognized as Safe (GRAS) by the Food and Drug Administration (FDA). Each Gelesis100 capsule contains thousands of hydrogel particles approximately the size of a grain of salt that expand to 100 times their dry weight. The pill is designed to act mechanically in the stomach and small intestine to increase satiety and decrease hunger, resulting in reduced caloric intake and weight loss. Gelesis was founded in 2006 in Boston, Massachusetts

    • $10M to $50M annual revenues
    • 11-50 employees
    • $84M raised in December, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  10. architectural photo of buildings during daytime


  11. Fluent BioSciences (Less than $1M)

    Fluent BioSciences is a privately funded venture developing high sensitivity molecular analytical products based on proprietary instrument-free micro-self-assembly technology which enables usage of extremely low molecular and cellular sample inputs.

    • Less than $1M annual revenues
    • 11-50 employees
    • $1.5M raised in July, 2018
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  12. KeraFAST ($1M to $10M)

    KeraFAST provides through our e-commerce portal the next generation of research tools for life science laboratories. They offer innovative research products and services that are not available elsewhere, including an incomparable assortment of unique bio-reagents, rare materials, compounds, labels, and probes. It was founded in 2010 and headquartered in Boston, Massachusetts.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $0.1M raised in February, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  13. two women sitting beside table using MacBooks


  14. Jnana ($1M to $10M)

    Jnana Therapeutics operates as a platform as a service company. The Company specializes in discovering and developing medicines that will make a difference for patients using the first drug discovery platform.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $50M raised in December, 2017
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  15. grayscale photo of people in room


  16. Psy Therapeutics ($1M to $10M)

    Psy Therapeutics is discovering and developing novel medicines to improve the lives of people affected by central nervous system (CNS) disorders.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $4M raised in October, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  17. people sitting in front of computer monitors


  18. Nanoview Biosciences ($1M to $10M)

    nanoView Diagnostics Inc. (dba NanoView Biosciences), is developing proprietary products that support research, translation and delivery of precision medicine. The Company was founded on a novel technology platform that uniquely identifies and characterizes exosomes. Our high-throughput, cost-effective analysis solutions enable life science researchers to better understand the biological role of exosomes and how to utilize them as biomarkers to provide improved insight for how diseases are diagnosed, treated and monitored.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $6M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  19. people sitting and using laptops


  20. Imbria Pharmaceuticals ($1M to $10M)

    Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need. We are propelled by a deep scientific interest in cellular metabolism and the mitochondria, and are guided by both values and a code of business conduct built upon our commitment to always put the patients, families and communities we serve at the forefront of all that we do.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $40.7M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  21. men using computers


  22. GliaCure (Less than $1M)

    GliaCure is a biotechnology company that focuses on the development of novel therapies for neurological and neuropsychiatric disorders based on glia targets. It specializes in the fields of healthcare, therapeutics and biotechnology. GliaCure was founded in 2011 and headquartered in Boston, Massachusetts.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1.6M raised in September, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  23. rectangular brown wooden table


  24. Precision Biopsy (Less than $1M)

    Precision Biopsy, a Boston, MA-based start up that aims to commercialize an optical biopsy technology designed to improve the accuracy and reliability of prostate biopsies and the diagnosis of prostate cancer.

    • Less than $1M annual revenues
    • 11-50 employees
    • $33.6M raised in October, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  25. tennis table in room


  26. Manifold Bio ($10M to $50M)

    Manifold Bio is a biotechnology company that features a platform that enables multiplexed quantitation of protein therapeutic designs, generating unprecedented data throughout the drug development process to unlock measurement-driven design. The company is building a protein barcoding platform to bring the power of multiplexed measurement to the development of protein therapeutics. It was founded in 2020 and headquartered in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $5.4M raised in September, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  27. grey wooden table and black leather rolling chairs


  28. Yumanity Therapeutics ($1M to $10M)

    Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award-winning protein folding expert, Susan Lindquist, and renowned biotech industry leader, Tony Coles, Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $33.6M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  29. man in black jacket sitting on chair


  30. Wave Life Sciences ($1M to $10M)

    WaVe Life Sciences is leading a revolution in nucleic acid therapeutics and was founded on the core principle that medicines should possess precisely controlled molecular structures. We and our strategic partners are advancing a portfolio of stereopure drug candidates that target underlying biology across a wide range of human diseases. WaVe maintains R&D facilities in Boston and Japan and was founded by two world-renowned scientific leaders, Gregory Verdine and Takeshi Wada. Dr. Verdine is an Erving Professor of Chemistry in the Harvard University Departments of Stem Cell and Regenerative Biology, Chemistry and Chemical Biology, and Molecular and Cellular Biology. Dr. Wada is a professor at Tokyo University of Science, Faculty of Pharmaceutical Sciences and Department of Medicinal and Life Science.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $30M raised in December, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  31. three women sitting around table using laptops


  32. DermBiont (Less than $1M)

    DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes (fungi, bacteria, viruses, etc.). The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $7.2M raised in October, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  33. people sitting on chairs near tables during daytime


  34. Nido Biosciences ($10M to $50M)

    Nido Biosciences currently operates in healthcare services. Nido Biosciences specializes in the fields of biotechnology, healthcare, and personal health. It is currently in stealth mode and was founded in 2018.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $18.4M raised in September, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  35. people using desktop computer inside office


  36. resTORbio ($1M to $10M)

    resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.The Company develops medicines and therapies to treat aging-related diseases and conditions such as cancer, heart disease, neurodegenerative diseases, and diabetes mellitus. resTORbio serves clients in the State of Massachusetts.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $40M raised in November, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  37. people sitting on black chairs


  38. ConcertAI ($10M to $50M)

    ConcertAI is a developer of medical research tool suite intended to design and deliver care-based oncology research and data analytics. It is an integrated real-world data and AI-driven solutions to transform how insights are generated and accelerate therapeutic innovations to patients. It was incorporated in 2018 and is based in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 5001-10000 employees
    • $150M raised in January, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  39. man in gray sweatshirt sitting on chair in front of iMac


  40. Nara Logics (Less than $1M)

    The Nara Logics Synaptic Intelligence platform is a recommendation and decision engine that works across a variety of information classes and customer verticals, using advanced techniques in neural networks and machine learning. The platform ingests and organizes data into networks involving data, people, objects, and actions. The platform learns, optimizes, and provides a real-time interaction system for querying recommendations and relations, along with dynamic analytics for understanding connections. Top companies use the platform across the enterprise from a direct customer product and offer recommendations to back-end corporate decision support needs. Nara Logics builds a synaptic network of explicit and inferred connections to create an intelligence layer on top of chaotic, siloed enterprise data for real-time, context-relevant recommendations and give the reasons behind them. The company was founded in 2011 and is based in Boston, Massachusetts, United States.

    • Less than $1M annual revenues
    • 11-50 employees
    • $5M raised in December, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  41. rolling armchair beside table


  42. Tal Medical (Less than $1M)

    Tal Medical is a clinical stage medical device company pioneering the development of a novel, non-contact, neuromodulatory device, for the treatment of psychiatric and neurological disorders. Tal has exclusively licensed Low Field Magnetic Stimulation (LFMS), a technology pioneered at McLean Hospital. Tal Medical is initially focusing on the development of LFMS for the treatment of major depressive disorder and bipolar depression. Both indications represent large unmet clinical needs in which the current standard of care has limited efficacy and treatment limiting side effects. Tal Medical is based in Boston and was founded in 2011 by PureTech Ventures and a leading group of neuroscientists and clinicians.

    • Less than $1M annual revenues
    • 11-50 employees
    • $14M raised in April, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  43. group of people sitting beside rectangular wooden table with laptops


  44. SOPHiA GENETICS ($50M to $100M)

    SOPHiA GENETICS combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing. The company aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning. This enables SOPHiA to provide equal benefits to all users, unite experts in a gold standard health-tech platform, and motivate expert knowledge sharing for a sustainable impact on future patients. It contributes to making the global healthcare system more sustainable. By helping healthcare professionals leverage their expertise and work together as a community, patients can receive equal access to better diagnoses and treatments. It combines the first two pillars of data-driven medicine, genomics, and radionics, the company ensures that the data used to help patients. Founded by Jurgi Camblong, Lars Steinmetz, and Pierre Hutter, SOPHiA GENETICS was incorporated in 2011. It has offices in Boston, Massachusetts, Switzerland, and France.

    • $50M to $100M annual revenues
    • 251-500 employees
    • $110M raised in October, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  45. photo of industrial machines near table


  46. ConquerX ($10M to $50M)

    ConquerX is a biotechnology company that provides innovative molecular profiling solutions to clinical trials in precision medicine. The company's flagship product, the EbeGen, is an electro-chemical biosensor capable of detecting multiple molecular targets such as DNAs, RNAs, mirRNAs at the same time, without the need for sequencing and qPCR and at 10-time more cost effective compared to current technologies.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.1M raised in January, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  47. brown wooden table and chairs


  48. Ginkgo Bioworks ($10M to $50M)

    Ginkgo Bioworks is a developer of biological engineering products and custom microbes across multiple markets. It designs, engineer, develops, tests, and licenses organisms. It discovers molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Gingko Bioworks also provides probiotic bacteria to protect the body from dangerous infections, and it generates libraries of molecules. It serves cultured ingredients, carbon mitigation, probiotics, and natural product discovery markets.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $70M raised in May, 2020
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  49. selective focus photography of desk lamp on table


  50. Xontogeny (Less than $1M)

    Xontogeny seeks to accelerate the development of life science technologies by providing entrepreneurs with the leadership, strategic guidance and operational support necessary to increase the probability of success in early drug and technology development. Through a differentiated approach, the Xontogeny team partners with the founding scientists and entrepreneurs of new ventures to support their vision while allowing a more efficient development model to benefit company founders and early equity holders.

    • Less than $1M annual revenues
    • 11-50 employees
    • $15M raised in May, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  51. men sitting of chair inside room


  52. Samsara Therapeutics ($1M to $10M)

    Samsara Therapeutics, Inc. is an R&D-stage biopharmaceutical platform company aiming to discover, develop and commercialize first-in-class therapeutics for the treatment of unmet medical needs and age-related diseases. Samsara's platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that extend healthy lifespan.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $3.2M raised in December, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  53. Cytrellis Biosystems (Less than $1M)

    Cytrellis Biosystems is a clinical stage medical technology company that designs and develops medical device for dermatology, scar reduction, and aesthetic medicine. Its devices are designed to remove sagging skin associated with aging without surgery or scarring, providing aesthetic practitioners an unprecedented ability to improve age related changes in skin. Cytrellis Biosystems was founded in 2011 and is based in Boston, Massachusetts.

    • Less than $1M annual revenues
    • 11-50 employees
    • $50M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  54. brown and white table and chairs


  55. Asimov ($1M to $10M)

    Asimov builds tools to program living cells. By integrating mammalian synthetic biology, computer-aided design, and machine learning, our multi-disciplinary team is advancing the design and manufacture of biologics and gene therapies.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $25M raised in January, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  56. people having meeting on rectangular brown table


  57. Cardurion Pharmaceuticals ($10M to $50M)

    Cardurion is a Boston-based cardiovascular biotechnology company developing new therapeutics for the treatment of heart failure and cardiovascular diseases. In July, 2017, Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals announced the creation of a new preclinical partnership to develop novel, next-generation therapeutics for the treatment of heart failure and cardiovascular diseases. The partnership with Cardurion follows Takeda’s strategy to leverage external innovation by placing selected assets and outstanding scientists in an entrepreneurial setting and enables the Discovery programs of Cardurion. In April 2018, Cardurion announced the Company entered an exclusive licensing agreement with Astellas to develop and commercialize CRD-733, a PDE-9 inhibitor with the potential to improve cardiac function in heart failure patients. With recent evidence supporting that inhibition of PDE-9 has potential to restore heart-protective mechanisms that are dysfunctional in heart failure, CRD-733 has the potential to address the cell-signaling breakdown that contributes to the progression of heart failure.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $10M raised in November, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  58. rectangular brown wooden table with chair lot inside building


  59. IGC BIO ($10M to $50M)

    IGC BIO is a biotechnology company based in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $2.2M raised in July, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  60. man and woman sitting at table


  61. Compass Therapeutics ($10M to $50M)

    Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabs and common light-chain based multispecific platforms to empirically identify combinations and multispecific with optimized activity. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engagers targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Boston Landing, Mass.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $60.5M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  62. people standiunmg


  63. Binx Health ($10M to $50M)

    Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer

    • $10M to $50M annual revenues
    • 11-50 employees
    • $2.6M raised in August, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  64. people sitting beside rectangular brown table with laptops


  65. Yobe Inc. (Less than $1M)

    Voice technologies continue to be plagued by issues stemming from background noise including other voices (i.e. errors in voice commands) and access/security using voice ID. Yobe’s innovative, patented approach to the Cocktail Party Problem is exponentially more effective than comparable technologies. Yobe uses Artificial Intelligence to identify unique voice biometrics within a noisy intake signal to identify and track individual voices. A byproduct of this capacity is that the signal of interest (the target person talking) can be enhanced for a better listening experience, speaker identification, or enables significantly improved performance for automatic speech recognition (ASR). To date, there is no other real-time technology that can manage all these capabilities in a single on-the-edge (on device, non-internet dependent) software solution that is agnostic to microphone inputs and form factor.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1.8M raised in May, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  66. two men using computers


  67. Aldatu Biosciences (Less than $1M)

    Aldatu Biosciences is a Boston, MA-based, early-stage biotechnology company developing innovative diagnostic tools based on its proprietary genotyping platform, PANDAA. Aldatu is committed to commercializing products that address diagnostic challenges in global health, primarily in HIV and other infectious diseases, and which improve both the quality of patient care and healthcare cost-efficiency.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in June, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  68. architectural photo of buildings during daytime


  69. CoWin Biosciences ($10M to $50M)

    CoWin Biosciences provides high-quality biology reagents in life science research and molecular diagnostics field.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $35.8M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  70. Biomiic ($1M to $10M)

    Biomiic is a fast and accurate microbiome sequencing service for the masses. They utilize high-throughput metagenomic (shotgun) sequencing to deliver high-dimensional, high-coverage genomic information about bacteria and viruses present in the human body

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.1M raised in October, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  71. two women sitting beside table using MacBooks


  72. Invetx ($10M to $50M)

    Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health. Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics. Working closely with best-in-class biotechnology companies, major investors and an extensive network of industry experts, Invetx is focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care. Invetx's network includes experts in both animal and human health, veterinary scientists and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $10.3M raised in September, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  73. grayscale photo of people in room


  74. Motif FoodWorks (Less than $1M)

    Motif makes ingredients for the next generation of plant-based and healthy foods. We use fermentation to brew vital proteins and nutrients that power your body and please your palate. They are collaborate with chefs, health experts, and food visionaries to create new building blocks for tomorrow’s food revolution. Motif combines tradition, innovation, and biotechnology to help build a more sustainable future, for everyone.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.8M raised in October, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  75. people sitting in front of computer monitors


  76. UV Light Care ($1M to $10M)

    UV Light Care is a medtech company focusing on Ultraviolet (UV) light technology for use in disinfection and other medical applications.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.5M raised in September, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  77. people sitting and using laptops


  78. Synspira ($1M to $10M)

    Synspira Therapeutics is focused on developing a rationally designed portfolio of products in cystic fibrosis and other rare diseases. Inspired by patients and frustrated by the limitations of conventional treatments, Synspira is advancing two novel products (SNSP113 and SNSP003) in order to provide better clinical outcomes and reduce treatment burden in Progressive Pulmonary Disease and Malabsorption Syndromes.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $14M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  79. men using computers


  80. LikeMinds ($1M to $10M)

    LikeMinds is a biotechnology company.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $5.2M raised in September, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  81. rectangular brown wooden table


  82. Zepteon ($10M to $50M)

    Zepteon is a privately held corporation that develops purification tools capable of separating antibodies with specific sugar structures, which are more potent against diseases like cancer. The corporation’s chromatography resins are being used to prepare material to evaluate the effects of a wide range of nonfucosylation levels in studies of antibody function. Its technology is also being used analytically, to determine antibody nonfucosylation levels as a function of cell culture conditions. Zepteon’s technology has the ability to support the preparation of a biosimilar antibody filing, increasing the chances of regulatory success and increasing speed to market. Zepteon was founded in 2012 by [Austin W. Boesch](https://www.crunchbase.com/person/austin-w--boesch) and [Glen R. Bolton](https://www.crunchbase.com/person/dr-glen-r--bolton#/entity). It is based in Boston, M.A.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.2M raised in April, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  83. tennis table in room


  84. Flaskworks ($1M to $10M)

    Flaskworks is improves the manufacture of immuno-therapeutics and dendritic cell-based vaccines.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.2M raised in September, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  85. grey wooden table and black leather rolling chairs


  86. QMENTA ($1M to $10M)

    QMENTA is a cloud-based medical image analysis and visualization platform that helps specialists provide better diagnosis and treatment for patients with brain diseases by quantifying changes in the patient’s brain. This helps to accelerate the discovery and development of new treatments for brain diseases. With QMENTA's cloud platform, specialists (researchers, neurologists, neurosurgeons, neuroradiologists) can upload medical images, have them processed, and access big datasets all in one place, within the browser, without the need to install and maintain any software. They can carry out advanced analyses with our proprietary tools and visualize the images with LeapMotion, thus we provide an intuitive, touch-less and sterilized way to bring these advanced imaging tools into the hands of the doctors, at the point of care, right in the operating room. Top-notch researchers all around the world have been using our platform that is infinitely scalable for data management, analysis, visualization, and sharing purposes. With our publicly accessible platform, you can advance your data and understanding of thousands, even millions of images. QMENTA is FDA Title 21 parts 11 & 820, Annex11, IEC 62304, GDPR, and HIPAA compliant. We take the privacy and security of patients data very seriously.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $3.5M raised in July, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  87. man in black jacket sitting on chair


  88. Akili Interactive Labs ($10M to $50M)

    Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games. It aims to develop a new type of electronic medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, with the potential to be developed at a fraction of the cost of traditional medical approaches. Akili’s cognitive engine enables three separate clinical game versions for remote data-capture, with features designed for patient engagement. Its proprietary adaptive mechanics allow the software to automatically personalize to the patient’s ability level with no clinician input required. Akili is based in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $13M raised in August, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  89. three women sitting around table using laptops


  90. BrainSpec (Less than $1M)

    BrainSpec is a comprehensive web-based software platform designed to make MRS technology accessible to clinicians and researchers alike. The software combines a linear combinations model based post-processing back-end that represents the most accurate method of measuring brain metabolites with a highly intuitive and user-friendly front-end web-based user interface. This combination allows for high analytical performance while maintaining ease of use and results in reduced case processing time, leading to higher output and lower costs

    • Less than $1M annual revenues
    • 1-10 employees
    • $1.7M raised in September, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  91. people sitting on chairs near tables during daytime


  92. Ensoma (Less than $1M)

    Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.

    • Less than $1M annual revenues
    • 11-50 employees
    • $70M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  93. people using desktop computer inside office


  94. Kumuda ($10M to $50M)

    Our powerful computational platform expands the small molecule drug target space to efficiently push discovery efforts towards successful first-in-class drugs in the clinic.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.1M raised in January, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  95. people sitting on black chairs


  96. Candescent Eye Holdings ($10M to $50M)

    Candescent Eye Holdings, LLC provides vision-related services including routine eye exams, cataract and LASIK surgery, and sales of prescription glasses and contact lenses. The company was incorporated in 2011 and is based in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $1.5M raised in March, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  97. man in gray sweatshirt sitting on chair in front of iMac


  98. Sonde Health (Less than $1M)

    Sonde Health is a digital medicine company developing voice-based technologies to transform the way we monitor and diagnose our mental and physical health.

    • Less than $1M annual revenues
    • 1-10 employees
    • $16M raised in April, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  99. rolling armchair beside table


  100. Embark ($1M to $10M)

    Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $10M raised in April, 2019
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  101. group of people sitting beside rectangular wooden table with laptops


  102. Advanced Proteome Therapeutics (Less than $1M)

    Cancer is a complex disease, and for therapies to be maximally effective, they must distinguish between normal and cancerous cells. Combination therapies have been employed to counter the multiple mechanisms that tumors use to evade the immune response and resist the efficacious effects of therapeutics. Despite continuing challenges, useful synergies have been obtained with a combination of individual drugs, and, as a result, a broad range of drug types are now being combined because of the promise and the compelling rationale behind combination therapy. Thus, effective treatment for cancer requires not only the discovery of individual drugs with antitumor activity, but also knowledge of the best way to combine these drugs.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.2M raised in May, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  103. photo of industrial machines near table


  104. Eliem Therapeutics ($1M to $10M)

    Eliem Therapeutics will leverage our world-class expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline. We are pioneering a new generation of analgesics to facilitate a better quality of life for patients.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $5M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  105. brown wooden table and chairs


  106. NeuroBo Pharmaceuticals ($1M to $10M)

    NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. Our Phase III-ready drug, NB-01, is based on natural sources and has shown successful Phase II results with excellent efficacy and safety in diabetic neuropathic pain (DNP) and we have strong preclinical data in both neuropathic pain and diabetes models showing a mode of action of NB-01 on nerve growth factor (NGF) release for nerve stabilization and regeneration. 40 to 50 percent of patients with diabetic peripheral neuropathy have some form of neuropathic pain and while existing drugs alleviate pain symptoms, they do not address the underlying disease. These current therapies also have a range of adverse effects, and only about 50 percent of patients respond positively. Additionally, the current therapies on the market were all initially approved for other disease states such as depression and fibromyalgia. NB-02, our lead Alzheimer’s drug, is in IND-enabling stage and has been extensively characterized in rodent models for mechanisms impacting Alzheimer’s disease (inhibition of AChE, pTau, amyloid-β, and stimulation of NGF for nerve growth. An aging population has resulted in an increase in the prevalence of Alzheimer’s disease, and the disease is a significant healthcare burden. Today, there are four approved drugs that manage the symptoms of Alzheimer’s disease, yet none of these four address disease modification.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $10M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  107. selective focus photography of desk lamp on table


  108. FluoroPharma (Less than $1M)

    FluoroPharma, Inc., a molecular imaging company, engages in the discovery, development, and commercialization of diagnostic imaging products for the positron emission tomography (PET) market. Its products include CardioPET, a modified fatty acid that provides insight into regions of metabolic insufficiency in myocardium, which is used to identify patients benefiting from PCI or revascularization and guide intervention, as well as to evaluate CAD in patients that cannot exercise. The company's products also include BFPET, a novel cardiovascular blood flow imaging agent that concentrates in healthy myocardial cells and it is used for detection of presumptive CAD in combination with stress testing, as well as for detection of CAD of multi-vessel disease. In addition, FluoroPharma develops VasoPET that accumulates in areas of inflammation, which is used for the evaluation of patients with acute coronary syndrome or risk of stroke, and for the therapy following an acute cardiac event or stroke. It focuses on the development of PET imaging agents for the detection and assessment of acute and chronic forms of coronary artery disease (CAD). The company was incorporated in 2003 and is based in Boston, Massachusetts. As of April 13, 2007, FluoroPharma, Inc. is a subsidiary of QuantRX Biomedical Corporation.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.2M raised in April, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  109. men sitting of chair inside room


  110. Emulate ($1M to $10M)

    Emulate is a private company that foces on commercializing Organs-on-Chips as an automated human bioemulation platform that achieves a new standard for mimicking true human physiology so that responses to medicines, chemicals, and diseases can be accurately predicted. Through co-innovation with collaborators and internal programs, Emulate is advancing product innovation, design, and safety across a range of applications in drug development, personalized medicine, agriculture, and chemical-based consumer products.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $19.3M raised in March, 2020
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  111. Boston MicroFluidics ($10M to $50M)

    Boston MicroFluidics is a biotechnology company that specializes in developing medical devices, point-of-care devices, capillary tubes, and disposable design.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $17.5M raised in August, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  112. brown and white table and chairs


  113. Adeo Health Science (Less than $1M)

    Adeo Health Science is a food and beverage company that offers organic foods. The company focuses on biotechnology and its driven by its mission of translating the latest food allergy prevention research into easy to use, organic, and trusted products for families.

    • Less than $1M annual revenues
    • 51-100 employees
    • $0.1M raised in November, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  114. people having meeting on rectangular brown table


  115. Cambrian Innovation ($10M to $50M)

    Cambrian Innovation is developing a portfolio of environmental solutions that help industrial, agricultural, and government customers save money while better managing and re-using their resources. Fueled initially by a 2006 NASA grant to explore how recent advances in bioelectricity can enhance water management in space, Cambrian has developed, scaled, and validated a pipeline of solutions that can recover resources from wastewater, eliminate energy input for wastewater treatment, radically reduce the cost of nitrate nitrogen treatment, and help agricultural operations monitoring their inputs more easily and efficiently.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $18M raised in October, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  116. rectangular brown wooden table with chair lot inside building


  117. Valo Health ($10M to $50M)

    Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning-anchored computation to transform the drug discovery and development process. By integrating data across the drug development lifecycle, the discovery and development of life-changing treatments can be accelerated, with the potential to reduce cost, time, and failure rate. The company's Opal Computational Platform™, a fully integrated, componentized, end-to-end drug development platform, offers a unique approach to therapeutic development, that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $190M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  118. man and woman sitting at table


  119. Sample6 ($1M to $10M)

    Sample6 is a synthetic-biology based bacteria diagnostic system capable of enrichment-free detection. Its technology detects as low as 1CFU/ml in just 4 hours. Its proprietary Bioillumination Platform was developed by Professor Tim Lu (MIT) and Dr. Michael Koeris in the lab of Professor James Collins at the Howard Hughes Medical Institute and Boston University. The platform allows for the engineering of bioparticles that target and “light up” specific unwanted bacteria—or specific groups of bacterial species. They couple this capability with highly sensitive sensor technology that detects low levels of pathogens to see results in minutes—right on-site—with no laboratory required. Sample6′s mission is to improve the health and safety of global consumers by building integrated systems that quickly and easily detect harmful and unwanted bacteria. They see applications in food production, retailing, healthcare, and beyond—anywhere humans and bacteria intersect.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $12.7M raised in August, 2016
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  120. people standiunmg


  121. Bioarray Therapeutics (Less than $1M)

    BIOARRAY's Therapeutics, Inc. (BIOARRAY) is a privately held start up biotechnology company founded in 2009 in Boston, MA. BIOARRAY is developing proprietary predictive diagnostic tests, based on cancer genes (markers), to choose to the most efficacious treatment for cancer patients beforehand, rather than the trial and error approach currently used.

    • Less than $1M annual revenues
    • 1-10 employees
    • $4M raised in October, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  122. people sitting beside rectangular brown table with laptops


  123. NuProbe ($1M to $10M)

    NuProbe is a biotechnology company based in Boston, Massachusetts.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $42M raised in January, 2021
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  124. two men using computers


  125. Symbiotix Biotherapies (Less than $1M)

    Symbiotix Biotherapies is a provider of a novel class of molecular therapeutics intended to develop molecules.The company's novel class of molecular therapeutics include a novel class of Treg-modulating therapeutics based on molecules derived from the human microbiom, enabling patients access first-in-class oral agents that improves their lives and helps them to treat themselves of inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5M raised in November, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  126. architectural photo of buildings during daytime


  127. Pear Therapeutics ($10M to $50M)

    Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $80M raised in December, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  128. Life Biosciences ($1M to $10M)

    Life Biosciences is a developer of drugs designed to promote longevity and find treatments for age-related diseases. Developer of drugs designed to promote longevity and find treatments for age-related diseases. The company's drugs help to combat the eight pathways of age-related decline and it's work addresses health decline due to aging as a systemic breakdown of the body, rather than a series of isolated events and conditions, enabling senior citizens to tackle age-related diseases with a view to ultimately extending healthy life spans.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $18.2M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  129. two women sitting beside table using MacBooks


  130. Karuna Therapeutics ($1M to $10M)

    Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $68M raised in March, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  131. grayscale photo of people in room


  132. TetraScience (Less than $1M)

    TetraScience develops hardware and software solutions to monitor and manage research experiments and log the data in the cloud. It offers sensors to monitor temperature, humidity, acceleration, etc.; camera to view experiment or tools; electric switches; adapters to connect hardware tools that comprise syringe pumps and wave generators; and timers. TetraScience serves scientists, engineers, managers, and safety officers. It has a strategic partnership with Dotmatics. Alok Tayi, Salvatore Savo, and Siping Wang founded TetraScience on October 21, 2014. It has its headquarters in Boston in Massachusetts.

    • Less than $1M annual revenues
    • 11-50 employees
    • $8M raised in October, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  133. people sitting in front of computer monitors


  134. Syntimmune ($10M to $50M)

    Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. Laurence and Richard Blumberg founded Syntimmune in 2013. Its headquarters is in Boston in Massachusetts.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $50M raised in June, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  135. people sitting and using laptops


  136. Atalanta Therapeutics ($10M to $50M)

    Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $110M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  137. men using computers


  138. Klogene Therapeutics, Inc. ($1M to $10M)

    Klogene is developing therapeutics for prevention and treatment of age related diseases based on increasing the level of the naturally occurring Klotho protein in the human body

    • $1M to $10M annual revenues
    • 11-50 employees
    • $0.3M raised in July, 2018
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  139. rectangular brown wooden table


  140. Beta Bionics ($1M to $10M)

    Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community. Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $63M raised in July, 2019
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  141. tennis table in room


  142. CleanBreak ($1M to $10M)

    CleanBreak is a biotechnology company based in Boston, Massachusetts.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $2M raised in June, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  143. grey wooden table and black leather rolling chairs


  144. Center for Regenerative Medicine ($1B to $10B)

    The Center for Regenerative Medicine (CReM) is a collaborative effort among scientists at Boston University and the Boston Medical Center that aims to advance stem cell research and regenerative medicine for the sake of patients. The research of the CReM is particularly focused on those suffering from diseases commonly seen at the Boston Medical Center. This research includes a focus on a technology discovered in 2006: induced pluripotent stem (iPS) cells.

    • $1B to $10B annual revenues
    • 1-10 employees
    • $1.7M raised in June, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  145. man in black jacket sitting on chair


  146. ORIG3N ($1M to $10M)

    ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $26.2M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  147. three women sitting around table using laptops


  148. Mytide Therapeutics (Less than $1M)

    Mytide is committed to providing peptides to serve a diverse array of applications. During their beta phase, they intend to work closely with partners to overcome challenges in synthesizing and purifying particular classes of peptides of interest, identify useful peptide modifications, and design and construct peptide libraries. We provide initial partners access to their cloud platform for immediate ordering, properties calculator, order tracking, and interactive data display with guaranteed purities of >90%, 3 mg quantities, and 5-day turnaround of peptides up to length 40 AA.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in September, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  149. people sitting on chairs near tables during daytime


  150. Akouos ($1M to $10M)

    Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process, enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $105M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  151. people using desktop computer inside office


  152. Prilenia (Less than $1M)

    Prilenia is a provider of biotechnology services. Improving the lives of patients and their families, by developing treatments for neurodegenerative and neurodevelopmental disorders, lies at the heart of Prilenia’s mission.

    • Less than $1M annual revenues
    • 1-10 employees
    • $62.5M raised in June, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  153. people sitting on black chairs


  154. Inozyme ($10M to $50M)

    Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $67.4M raised in April, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  155. man in gray sweatshirt sitting on chair in front of iMac


  156. Joyn Bio ($1M to $10M)

    Joyn Bio is a joint venture founded by Bayer and Ginkgo Bioworks developing probiotics for plants to provide growers with next generation solutions to their biggest challenges. Joyn Bio’s first area of focus will be on engineering microbes that provide cereal crops with their nitrogen needs to reduce agriculture’s reliance on nitrogen fertilizer and its environmental impact. Joyn Bio brings together microbiologists, synthetic biologists, plant scientists, and ecologists at its headquarters in Boston, Massachusetts and its plant research facility in West Sacramento, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $100M raised in March, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  157. rolling armchair beside table


  158. Biofourmis (Less than $1M)

    Biofourmis is a biotechnology company that augments personalized care and therapies using digital therapeutics. The company discovers, develops, and delivers clinically validated software-based therapeutics to enable better outcomes for patients. These solutions include advanced tools for clinicians to deliver personalized care and cost-effective solutions for payers. Biofourmis was founded in 2015 and headquartered in Boston, Massachusetts.

    • Less than $1M annual revenues
    • 101-250 employees
    • $100M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  159. group of people sitting beside rectangular wooden table with laptops


  160. Rhythm Pharmaceuticals ($1M to $10M)

    Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Their lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. They believe that setmelanotide, for which they have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin 4, or MC4, pathway deficiencies. The MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight, and peptide therapeutics are uniquely suited to activating this target.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $172.5M raised in October, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  161. photo of industrial machines near table


  162. Aerovate Therapeutics ($10M to $50M)

    Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's program is a potentially disease-modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of the drug imatinib that delivers this medicine directly to diseased lung tissues while reducing systemic adverse side effects. The company was founded and incubated by RA Capital Management, a multi-stage investment manager focused on healthcare and life sciences.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $72.6M raised in August, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  163. brown wooden table and chairs


  164. Back Bay Life Science Advisors (Less than $1M)

    Back Bay Life Science Advisors provides strategy consulting and transaction advisory services to the life science industry. Our expertise spans the continuum of stage, sector, and geography, across every therapeutic class. We work with local and global biopharmaceutical and medical technology sectors on the buy and sell side of transaction execution, from gleam-in-the-eye preclinical technology platforms to $2 billion established brands.

    • Less than $1M annual revenues
    • 11-50 employees
    • $1.6M raised in November, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  165. selective focus photography of desk lamp on table


  166. Centrexion ($1M to $10M)

    Centrexion Therapeutics is focused on developing new therapies for moderate to severe chronic pain that address the safety and efficacy gaps in the current treatment paradigm.We aim to relieve the suffering associated with chronic pain by creating treatments that address the safety and efficacy gaps in the current treatment paradigm.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $40.5M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  167. men sitting of chair inside room


  168. Accreon ($10M to $50M)

    Accreon solves critical business needs for healthcare, government, and business clients through technology-enabled solutions. The firm focuses on delivering innovative solutions for Healthcare and Life Sciences. It was founded in 2008 and headquartered in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $5.5M raised in April, 2015
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  169. Medrhythms (Less than $1M)

    Medrhythms is a digital therapeutics company that utilizes sensors, music, and software to develop evidence-based, neurologic interventions to measure and improve walking. The company was founded in 2013 and is headquartered in Boston, Massachusetts.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5.3M raised in June, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  170. brown and white table and chairs


  171. Symbiosis Pharmaceutical Services ($1M to $10M)

    Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials. We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products. Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $2M raised in December, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  172. people having meeting on rectangular brown table


  173. Partner Therapeutics ($1M to $10M)

    Partner Therapeutics is a developer of drugs for oncology treatment. The company focuses on the development and commercialization of approved and late-stage therapies that improve treatment outcomes and reduce the total cost of care for cancer. Its development spans the entire range of cancer therapy from primary treatments to supportive care.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $60M raised in February, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  174. rectangular brown wooden table with chair lot inside building


  175. Pyxis Oncology ($10M to $50M)

    Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $22M raised in July, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  176. man and woman sitting at table


  177. BrickBio (Less than $1M)

    BrickBio is a developer of a bioconjugation platform intended for research of site-specific modification of proteins. The company's platform can optimize any conjugate with the selective modification of a number of distinct websites on a single protein through its prokaryotic and eukaryotic expression programs, thereby providing hospitals with amino acid coupled therapeutics to improve protein characteristics.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5M raised in November, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  178. people standiunmg


  179. Orbita ($1M to $10M)

    Orbita is the leading digital platform for voice and chatbot virtual assistant solutions in healthcare. Orbita powers omni-channel virtual assistants, bots, and other conversational experiences that improve patient engagement, reduce costs of care, and improve outcomes. https://www.youtube.com/channel/UCdcL0Oc_9L6CbTS7DeZ6UBg

    • $1M to $10M annual revenues
    • 11-50 employees
    • $9M raised in May, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  180. people sitting beside rectangular brown table with laptops


  181. Portela Soni Medical (Less than $1M)

    Portela Soni Medical is a developer of a catheter device designed to solve problems for patients in novel and innovative ways. The company's device has the potential to reduce catheter-associated urinary tract infections and it uses a proprietary added functionality that is designed to reduce bacterial growth and also adds a high value for providers as it can be used for targeted therapeutic delivery to the urinary tract, providing physicians with a new treatment modality to improve patient outcome.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.4M raised in March, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  182. two men using computers


  183. Anodyne Nanotech (Less than $1M)

    Anodyne Nanotech is a preclinical-stage biotech company that develops differentiated, transdermal forms of high-value drugs. The company’s first practical and cost-effective platform, Hero Patch, delivers clinically meaningful doses of macromolecules such as monoclonal antibodies or small molecules for fast and sustained delivery. Anodyne Nanotech was founded in 2019 by Jake Lombardo, Konstantinos Tzortzakis, and Hojatollah Rezaei Nejad.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2M raised in August, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  184. architectural photo of buildings during daytime


  185. Entrada Therapeutics ($1M to $10M)

    Entrada Therapeutics’ mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada’s technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company's novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol. For more information, please visit www.entradatx.com.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $59M raised in December, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  186. Motus Therapeutics ($100M to $500M)

    Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

    • $100M to $500M annual revenues
    • 11-50 employees
    • $1M raised in September, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  187. two women sitting beside table using MacBooks


  188. Exonics Therapeutics ($1M to $10M)

    Exonics’ laboratory has demonstrated the ability to use adeno-associated virus (AAV) to deliver a payload based on CRISPR/Cas9 technology that can identify and correct exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $40M raised in November, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  189. grayscale photo of people in room


  190. CATALOG ($1M to $10M)

    CATALOG is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to store digital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $10M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  191. people sitting in front of computer monitors


  192. Profility ($1M to $10M)

    Profility Inc. was established by Mr. Erez Schachter and colleagues in 2011 with a goal of improving healthcare outcomes. Profility is currently focusing its efforts on an engine that will initially change decision making in long-term care and later, in medical practice in general. Profility’s ground-breaking profiling technology revolutionizes the ability to make accurate individualized predictions that enable the delivery of customized care. The world’s population is rapidly aging, on the other hand, we see a steady rise in life expectancy; the combination of these two factors mean that more individuals lose their functional independence yet live for many more years, often requiring long-term care services. A person’s placement in an appropriate care environment, at the right time – has become crucial. Today, growing proportions of placement decisions are inappropriate or wrong, leading to great inefficiencies in care, as well as an annual waste of tens of billions of Euros, worldwide.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.2M raised in March, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  193. people sitting and using laptops


  194. Reverie Labs (Less than $1M)

    Reverie Labs (YC W18) is building a pharma company from scratch, using computation. Reverie Labs accelerates preclinical drug development by applying machine learning to lead generation & optimization.

    • Less than $1M annual revenues
    • 1-10 employees
    • $25M raised in February, 2021
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  195. men using computers


  196. Entrega Bio (Less than $1M)

    Entrega Bio offers a proprietary technology that makes injectable substances available orally. Its technology has the potential to deliver a wide variety of biological molecules, drug substances, and nanoparticles. Entrega Bio collaborates with pharma and non-pharma industry partners to develop the platform for innovative therapeutic and diagnostic modalities. This platform enables novel applications in a variety of fields such as disease management and tracking in the burgeoning mobile health arena. Entrega Bio is based in Boston, Massachusetts, United States.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5M raised in December, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  197. rectangular brown wooden table


  198. Scorpion Therapeutics ($10M to $50M)

    Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $162M raised in January, 2021
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  199. tennis table in room


  200. Meenta ($1M to $10M)

    Meenta is a cloud-sequencing platform where scientists can instantly find, book, and send samples to host instruments. Meenta makes it easy for scientists to find instruments in minutes and for hosts to offer their instruments for bookings with just a few clicks.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $1.5M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  201. grey wooden table and black leather rolling chairs


  202. Cure Forward ($1M to $10M)

    Cure Forward is a healthcare company that specializes in the fields of genomic medicine, consumer healthcare, oncology, and clinical trials. The company helps cancer patients and physicians access advanced treatments in oncology. It was founded in 2014 and is headquartered in Boston, Massachusetts.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $4.5M raised in May, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  203. man in black jacket sitting on chair


  204. Elucid Bio ($1M to $10M)

    Based in the Boston biotech and medtech hub, Elucid Bioimaging is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, vascuCAP, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $3M raised in June, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  205. three women sitting around table using laptops


  206. Oncolinx (Less than $1M)

    Oncolinx, in conjunction with the National Cancer Institute is developing the next generation of targeted cancer therapies: antibody-drug conjugates (ADCs). Oncolinx ADCs carry a patented, immune-activating drug payload called the Azonafide directly, and exclusively, to cancer cells, and not healthy cells, thereby avoiding many of the adverse side-effects of chemotherapy. The Oncolinx platform is partnered with more than 14 leading pharmaceutical companies and 6 academic labs all over the world— concurrently developing ADCs across 30 different cancer indications. Oncolinx aims to enter clinical trials with a partnered program in mid-2017.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1M raised in October, 2016
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  207. people sitting on chairs near tables during daytime


  208. SciFluor Life Sciences ($1M to $10M)

    SciFluor Life Sciences is an Allied Minds funded company with a late-stage fluorination technology that improves drug properties such as metabolic stability, potency, bioavailability, and blood-brain-barrier penetration. The company's late-stage fluorination technology is licensed exclusively from Harvard University. SciFluor's technology enables end-stage or any-stage fluorination of a wide variety of organic compounds.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $30M raised in April, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  209. people using desktop computer inside office


  210. SeromYx Systems ($10M to $50M)

    SeromYx Systems is a biotech company that provides insight into the immune function to discover and develop vaccines, immunotherapies, drugs, and diagnostics. The company was formed in July 2019 to commercialize the Systems Serology platform developed by Dr. Galit Alter at the Ragon Institute of Harvard/MIT/MGH, with the support of DARPA and the Bill and Melinda Gates Foundation

    • $10M to $50M annual revenues
    • 1-10 employees
    • $3.1M raised in July, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  211. people sitting on black chairs


  212. Proterris ($10M to $50M)

    Proterris, a P2 clinical-stage firm, has pooled a dominant IP position in therapeutic uses of inhaled and small-molecule carbon monoxide. Proterris has prioritized CO development in delayed graft function (DGF), acute liver failure, and non-alcoholic steatohepatitis (NASH), with significant opportunities in a number of other indications, including but not limited to acute kidney injury (AKI), renal fibrosis, and idiopathic pulmonary fibrosis (IPF). It is headquartered in Boston, Massachusetts.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $2M raised in July, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  213. man in gray sweatshirt sitting on chair in front of iMac


  214. Leuko (Less than $1M)

    Leuko Labs develops non-invasive white blood cell monitoring device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Though its white blood cell monitoring device PointCheck, immunosuppressed patients can now be tested more frequently, moving towards improved quality of life and improved clinical outcomes.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2M raised in July, 2019
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  215. rolling armchair beside table


  216. ImmuneID ($10M to $50M)

    ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $17M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  217. group of people sitting beside rectangular wooden table with laptops


  218. Atea Pharmaceuticals ($1M to $10M)

    Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $215M raised in May, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  219. photo of industrial machines near table


  220. CONTINUUS Pharmaceuticals (Less than $1M)

    CONTINUUS Pharmaceuticals works with pharmaceutical and generic companies under a Build-Own-Operate model. They design, build, and run the manufacturing process directly at the client site. This novel business model provides its clients with an exceptional, ”one-shop solution” for their entire development and manufacturing cycle. CONTINUUS Pharmaceuticals is leveraging a novel continuous manufacturing platform called Integrated Continuous Manufacturing (ICM), initially developed through an $85 M joint research project between Novartis and MIT. In addition, the company is currently collaborating with hospital systems and pharmacy chains to establish its own generic business, where high-quality, low-cost drugs will be manufactured in the United States.

    • Less than $1M annual revenues
    • 11-50 employees
    • $5M raised in September, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  221. brown wooden table and chairs


  222. Miach Orthopaedics ($1M to $10M)

    Miach Orthopaedics is a medical device company that develops bio-engineered surgical implants to facilitate new tissue growth. The company's product is the Bridge-Enhanced ACL Repair technology as a viable alternative to conventional ACL reconstruction for patients who have withstand an anterior cruciate ligament injury. Miach Orthopaedics was founded on 2016 and is headquartered in Westborough, Massachusetts.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $22.5M raised in September, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  223. selective focus photography of desk lamp on table


  224. Farcast ($1M to $10M)

    Farcast is a clinical diagnostic company whose mission it is to illuminate personal treatment truth of a cancer patient. The Farcast technology core is a human tumor micro-environment that enables oncologists and drug developers to test individual tumors to determine treatment response profiles. The company has its headquarters in Boston in Massachusetts, and operates a lab in Bangalore in India.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $40M raised in July, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  225. men sitting of chair inside room


  226. Cerevel Therapeutics ($1M to $10M)

    Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $350M raised in October, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  227. GRO Biosciences (Less than $1M)

    GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.

    • Less than $1M annual revenues
    • 11-50 employees
    • $3.5M raised in March, 2019
    • 7 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  228. brown and white table and chairs


  229. inviCRO ($10M to $50M)

    inviCRO is an image science company that provides advanced data analysis services and software in the growing field of pre-clinical imaging research. In collaboration with partner imaging centers, inviCRO facilitates full-service contract research imaging services utilizing SPECT, PET, MR, CT and Optical imaging technologies. To this effort, inviCRO has developed a product line of dedicated analysis and software services addressing image processing and reporting required of a pre-clinical laboratory running imaging trials.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $45.8M raised in February, 2016
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  230. people having meeting on rectangular brown table


  231. Alivio Therapeutics ($1M to $10M)

    Alivio Therapeutics is pioneering targeted disease immunomodulation as a novel strategy to treat a range of chronic and acute inflammatory disorders. Targeted disease immunomodulation involves tuning the immune system exclusively at the site of disease in the body, with minimal impact on the rest of the immune system. This long sought-after approach has potential to treat a range of chronic and acute inflammatory disorders including ones that would otherwise be difficult to treat. Alivio has exclusive rights to a proprietary inflammation-targeting technology, based on the research of Dr. Karp (BWH/HMS) and Dr. Robert Langer (MIT), which is the first technology to reproducibly show the ability to target immunomodulatory compounds to inflamed tissue, which can lead to dramatic improvements in treatment efficacy with major reductions in systemic effects. The platform has been validated in multiple labs and preclinical models of inflammation, including models where the inflammation occurred in different parts of the body (e.g., the GI system, the bladder, joints, skin, etc.). The technology could potentially be used with a variety of medications (e.g., small molecules, biologics, and nucleic acids) both independently or in combination, and is designed to be administered orally or via other routes. With this platform, Alivio aims to address the dozens of conditions where inflammation is a central part of the underlying disease pathology, but where targeted and effective treatment options are lacking.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $3.3M raised in September, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  232. rectangular brown wooden table with chair lot inside building